Brendan W Lunn1, Laurel A Littrell1, Doris E Wenger1, Stephen M Broski2. 1. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. broski.stephen@mayo.edu.
Abstract
OBJECTIVE: To examine the imaging characteristics of intramuscular myxomas (IM) and myxoid liposarcomas (MLS) on 18F-FDG PET/CT and MRI. MATERIALS AND METHODS: With IRB approval, our institutional imaging database was searched for pathologically proven IM and MLS evaluated by 18F-FDG PET/CT and MRI. PET/CT and MRI imaging characteristics were recorded and correlated with pathologic diagnosis. RESULTS: We found eight patients (2 M, 6 F) with IM (mean age 65.6 ± 10.4 years) and 16 patients (7 F, 9 M) with MLS (mean age 42.8 ± 16.3 years). MRI was available in 7/8 IM and 15/16 MLS patients. There was no significant difference between the two groups in SUVmax (IM 2.7 ± 0.8, MLS 3.0 ± 1.0; p = 0.35), SUVmean (1.7 ± 0.4, 1.5 ± 0.5; p = 0.40), total lesion glycolysis (101.8 ± 127.3, 2420.2 ± 4003.3 cm3*g/ml; p = 0.12), metabolic tumor volume (62.3 ± 71.1, 1742.9 ± 3308.0 cm3; p = 0.17) or CT attenuation (p = 0.70). MLS occurred in younger patients (p = 0.0015), were larger (16.4 ± 8.2 vs. 5.6 ± 2.5 cm; p = 0.0015), more often T1 hyperintense (p = 0.03), with nodular enhancement (p = 0.006), and macroscopic fat on CT (p = 0.0013) and MRI (p = < 0.001) compared to myxomas. CONCLUSIONS: IM and MLS most commonly demonstrate low-grade FDG activity and overlapping metabolic measures on PET/CT. MRI is useful in differentiation, but MLS can present without macroscopic fat on MRI, underscoring the importance of radiologic-pathologic correlation for accurate diagnosis.
OBJECTIVE: To examine the imaging characteristics of intramuscular myxomas (IM) and myxoid liposarcomas (MLS) on 18F-FDG PET/CT and MRI. MATERIALS AND METHODS: With IRB approval, our institutional imaging database was searched for pathologically proven IM and MLS evaluated by 18F-FDG PET/CT and MRI. PET/CT and MRI imaging characteristics were recorded and correlated with pathologic diagnosis. RESULTS: We found eight patients (2 M, 6 F) with IM (mean age 65.6 ± 10.4 years) and 16 patients (7 F, 9 M) with MLS (mean age 42.8 ± 16.3 years). MRI was available in 7/8 IM and 15/16 MLSpatients. There was no significant difference between the two groups in SUVmax (IM 2.7 ± 0.8, MLS 3.0 ± 1.0; p = 0.35), SUVmean (1.7 ± 0.4, 1.5 ± 0.5; p = 0.40), total lesion glycolysis (101.8 ± 127.3, 2420.2 ± 4003.3 cm3*g/ml; p = 0.12), metabolic tumor volume (62.3 ± 71.1, 1742.9 ± 3308.0 cm3; p = 0.17) or CT attenuation (p = 0.70). MLS occurred in younger patients (p = 0.0015), were larger (16.4 ± 8.2 vs. 5.6 ± 2.5 cm; p = 0.0015), more often T1 hyperintense (p = 0.03), with nodular enhancement (p = 0.006), and macroscopic fat on CT (p = 0.0013) and MRI (p = < 0.001) compared to myxomas. CONCLUSIONS: IM and MLS most commonly demonstrate low-grade FDG activity and overlapping metabolic measures on PET/CT. MRI is useful in differentiation, but MLS can present without macroscopic fat on MRI, underscoring the importance of radiologic-pathologic correlation for accurate diagnosis.
Authors: Stephen M Fisher; Robert Joodi; Ananth J Madhuranthakam; Orhan K Öz; Rohit Sharma; Avneesh Chhabra Journal: Eur J Radiol Date: 2016-05-11 Impact factor: 3.528
Authors: Matthias R Benz; Sarah M Dry; Fritz C Eilber; Martin S Allen-Auerbach; William D Tap; David Elashoff; Michael E Phelps; Johannes Czernin Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Kenneth Sheah; Hugue A Ouellette; Martin Torriani; G Petur Nielsen; Susan Kattapuram; Miriam A Bredella Journal: Skeletal Radiol Date: 2007-12-21 Impact factor: 2.199
Authors: Jonelle M Petscavage-Thomas; Eric A Walker; Chika I Logie; Loren E Clarke; Dennis M Duryea; Mark D Murphey Journal: Radiographics Date: 2014 Jul-Aug Impact factor: 5.333
Authors: Alonja Reiter; Katharina Trumm; Tobias M Ballhause; Sebastian Weiss; Karl-Heinz Frosch; Alexander Korthaus; Ulrich Bechler; Anna Duprée; Andreas Luebke; Peter Bannas; Carsten W Schlickewei; Matthias H Priemel Journal: Diagnostics (Basel) Date: 2022-06-28